Protein profiling plays an essential part in today’s biomedical research, striving to improve patients’ quality of life by using molecular signatures for diagnosis and treatment guidance.
At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Therefore, our internal development pipeline of innovative biomarker signatures for precision medicine is based on this powerful platform.
In the focus of our development activities are a biomarker signature for prediction and early diagnosis of peri-operative acute kidney injury as well as markers to predict a severe COVID-19 disease next to precision oncology.
In addition, we offer services based on our scioDiscover profiling platform and R&D collaborations for the discovery and validation of novel biomarkers, for drug target screening, and for the analysis of pathway activity as well as mode-of-action analyses.
The scioDiscover sample-to-result service is used by our customers from pharmaceutical industry and in biomedical research centres for Target discover & verification, Biomarker discovery & verification, Mode of action analysis, Early toxicology, Pathway profiling, Cell line / animal model selection & control
scioUbi is a high-content protein expression and ubiquitination level analysis.
With scioUbi you can analyse up to 1,300 proteins in a single assay.
scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation.
Protein profiling of 119 cytokines / chemokine and 141 cell surface markers in a single assay. This analysis is ideally suitiable to profile the immune response to external stimuli.